High-Throughput TB Vaccine Antigen Discovery
High-Throughput TB Vaccine Antigen Discovery
批准号:
10676485
负责人:
Amanda Martinot
金额:
$13.75万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-06-01 至 2024-08-31
关键词:
Adenovirus VectorAdultAnimal ModelAnimalsAntigensAntitubercular AgentsBCG LiveBacille Calmette-Guerin vaccinationBacteriologyBar CodesCD8-Positive T-LymphocytesCellsChildChildhoodClinical TrialsCommunicable DiseasesCoupledDNA VaccinesDataDevelopmentDiseaseExpression LibraryFailureGene LibraryGenesGenomeGoalsGrowthHIVHIV vaccineHeadImmuneImmune responseImmunityImmunodominant AntigensImmunologyInfectionInterferon Type IIIsraelKnowledgeLaboratoriesLibrariesLymphocyte antigenMedical centerMeningeal TuberculosisMentorshipMicrobiologyModelingMucous MembraneMusOpen Reading FramesPersonsPopulationPositioning AttributeProteinsProteomePulmonary TuberculosisResearchResearch PersonnelSurfaceT cell responseT memory cellT-LymphocyteTestingTrainingTuberculosisTuberculosis VaccinesVaccine AntigenVaccine DesignVaccine ResearchVaccinesWhole Cell VaccineWorkZIKV infectiondeep sequencingdesigngenome-wideimmunogenicimmunogenicityimmunopathologyin vivoinnovationmouse modelmycobacterialnew technologynovelnovel vaccinespreventprimary endpointprotective efficacyresponseskillstranslational medicinevaccination against tuberculosisvaccine candidatevaccine developmentvaccine discoveryvaccine efficacyvaccine strategyvaccinologyvirology
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract:
Approximately one third of the world's population is infected with latent tuberculosis (LTBI). While BCG
vaccination protects some children against pediatric tuberculous meningitis, it does not prevent the most
prevalent form of disease, pulmonary TB disease in adults. To date, every new tuberculosis (TB) vaccine
candidate has failed in large-scale clinical trials and no known immune correlates of vaccine protection for TB
have been validated. Failure of new TB vaccines such as MVA-85A, despite generating high-magnitude Th1
immune responses against the immunodominant antigen, Ag85A, is likely related to the exclusive use of
immunodominant antigens in these vaccines, despite poor correlation of immunodominant responses with
vaccine efficacy. These facts highlight a critical need for discovery of novel subdominant TB antigens for use in
TB vaccines that can enhance functional immunity and bacterial killing. Here we propose a novel TB antigen
discovery platform that enables systematic and unbiased probing of a TB genome-wide DNA vaccine
library with the overall objective to identify new TB antigens. Our specific aims are to generate immune
responses to pooled subdominant antigens in mice and to identify novel subdominant immunogens
with capacity to induce protective immunity. We aim to do this by in vivo interrogation of the TB
proteome using the mouse challenge model. Our long-term goal is to inform TB vaccine design and to
uncover novel immune correlates of vaccine protection for TB. Achieving these aims has the capacity to
transform the TB vaccine field and contribute to the development of an efficacious TB vaccine. The Barouch
laboratory at Beth Israel Deaconess Medical Center leads in vaccine design and discovery for diseases such as
HIV and Zika virus infection. I aim to synergize my expertise in TB bacteriology and animal models with
enhanced training in immunology and vaccinology at the Center for Virology and Vaccine Research to gain the
skills necessary to position myself to become a leader in TB vaccine discovery as a principle investigator and
head of my own research group.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1371/journal.ppat.1009096
发表时间:
2020-12
期刊:
PLoS pathogens
影响因子:
6.7
作者:
[Martinot AJ, Blass E, Yu J, Aid M, Mahrokhian SH, Cohen SB, Plumlee CR, Larocca RA, Siddiqi N, Wakabayashi S, Gardner M, Audette R, Devorak A, Urdahl KB, Rubin EJ, Barouch DH]
通讯作者:
Barouch DH
DOI:
10.1016/j.cell.2021.05.040
发表时间:
2021-06-24
期刊:
Cell
影响因子:
64.5
作者:
[He X, Chandrashekar A, Zahn R, Wegmann F, Yu J, Mercado NB, McMahan K, Martinot AJ, Piedra-Mora C, Beecy S, Ducat S, Chamanza R, Huber SR, van Heerden M, van der Fits L, Borducchi EN, Lifton M, Liu J, Nampanya F, Patel S, Peter L, Tostanoski LH, Pessaint L, Van Ry A, Finneyfrock B, Velasco J, Teow E, Brown R, Cook A, Andersen H, Lewis MG, Schuitemaker H, Barouch DH]
通讯作者:
Barouch DH
Digital pathology for defining myeloid cell-mediated lung injury during acute SARS CoV-2 Infection in hamsters
-
批准号:10348996
-
项目类别:
-
资助金额:$24.75万
-
财政年份:2022
-
负责人:Amanda Martinot
-
依托单位:
Digital pathology for defining myeloid cell-mediated lung injury during acute SARS CoV-2 Infection in hamsters
-
批准号:10700811
-
项目类别:
-
资助金额:$20.63万
-
财政年份:2022
-
负责人:Amanda Martinot
-
依托单位:
Myeloid-Derived Suppressor Cells in Tuberculosis Granuloma Structure and Function
-
批准号:10247081
-
项目类别:
-
资助金额:$25.02万
-
财政年份:2020
-
负责人:Amanda Martinot
-
依托单位:
Myeloid-Derived Suppressor Cells in Tuberculosis Granuloma Structure and Function
-
批准号:10082741
-
项目类别:
-
资助金额:$22.39万
-
财政年份:2020
-
负责人:Amanda Martinot
-
依托单位:
High-Throughput TB Vaccine Antigen Discovery
-
批准号:9767017
-
项目类别:
-
资助金额:$15.85万
-
财政年份:2019
-
负责人:Amanda Martinot
-
依托单位:
High-Throughput TB Vaccine Antigen Discovery
-
批准号:10242744
-
项目类别:
-
资助金额:$15.85万
-
财政年份:2019
-
负责人:Amanda Martinot
-
依托单位:
High-Throughput TB Vaccine Antigen Discovery
-
批准号:10468128
-
项目类别:
-
资助金额:$15.85万
-
财政年份:2019
-
负责人:Amanda Martinot
-
依托单位:
海外基金